Atherosclerotic Cardiovascular Disease Clinical Trials

124 clinical trials for Atherosclerotic Cardiovascular Disease across international registries, including 23 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a) — RECRUITING · PHASE3
• Lp(a) Lowering Study of Pelacarsen (TQJ230) With Background Inclisiran in Participants With Elevated Lp(a) and Established ASCVD — RECRUITING · PHASE3
• Health for Hungary (H4H) - Longitudinal Collection of Blood Samples and Corresponding Data — RECRUITING
• Pelacarsen Roll-over Extension Program — RECRUITING · PHASE3
• Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity — RECRUITING · PHASE3
• A Real-World Study of Long-Term Adherence and Persistence to Inclisiran, Evolocumab, and Alirocumab — RECRUITING
• The Coronary Artery Calcium and Troponins in Rheumatoid Arthritis (CAT-RA) Study — RECRUITING
• Effects of Pitavastatin or Combination of Pitavastatin and Ezetimibe on Glucose Metabolism Compared to AtoRvastatin in atheroscLerotic Cardiovascular Disease Patients With Metabolic Syndrome: The EZ-PEARL Randomized Trial — RECRUITING · NA
• Placebo-controlled Study of Single and Multiple Ascending Doses of UDP-003 in Healthy Human Participants and Followed by an Open-label Patient Cohort — RECRUITING · PHASE1
• A Phase III Study To Evaluate the Efficacy And Safety Of HRS9531 In Participants With Atherosclerotic Cardiovascular Disease — RECRUITING · PHASE3
• Dual PCSK9 Inhibition With Inclisiran and Alirocumab in Secondary Prevention — RECRUITING · PHASE4
• Study to Evaluate the Impact of a Targeted Lipid Optimization Program on LDL-C Control in At-risk Adult Patients With Dyslipidemia — RECRUITING · PHASE4
• Aspirin 50 mg vs. 100 mg in Elderly Cardiovascular Disease Patients — RECRUITING
• Long-term Follow-up of Participants Dosed With an Investigational Gene Editing Therapy for Cardiovascular Disease — RECRUITING
• Study of the Determinants of Coronary Atherosclerosis in Familial Hypercholesterolemia (ATHERO-FH Study) — RECRUITING · NA
• Polypill and Colchicine for Risk Reduction in Atherosclerotic Cardiovascular Disease — RECRUITING · PHASE3
• Fish Oil, Metformin and Heart Health in PCOS — RECRUITING · PHASE1
• Polygenic Risk Score Implementation and Stratification for Managing Blood Pressure — RECRUITING · NA
• Lipoprotein(a) Levels in Patients With Atherosclerotic Cardiovascular Diseases in Russia — RECRUITING
• A Pragmatic INitiative for LDL-C Management by a CLinical Pharmacist-Led Team Among Atherosclerotic CardiovascUlar DisEase Patients — RECRUITING · NA
• The Prevent Coronary Artery Disease Trial — RECRUITING · PHASE3
• Coated or Chewable Aspirin and a Hybrid Strategy to Mitigate Adverse Effects of Air Pollution in Stable Atherosclerotic Disease — RECRUITING · NA
• LDL Cholesterol TARGETs in OLDer Patients (Age≥75 Years) With ASCVD (TARGET OLD) — RECRUITING · NA
• A single arm, multicenter, open-label extension (OLE) trial to evaluate long-term safety and tolerability of pelacarsen (TQJ230) in participants who completed the parent Lp(a)HORIZON trial — TERMINATED · PHASE3
• A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of Orticumab in Participants with Prior Myocardial Infarction who have Elevated Coronary Inflammation Based on Fat Attenuation Index (FAI) Score Assessed by Coronary Computed Tomography Angiography (CCTA) — TERMINATED · PHASE2
• A randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy, safety, and tolerability of pelacarsen (TQJ230) with background inclisiran in participants with atherosclerotic cardiovascular disease, and elevated LDL-C and Lp(a) — TERMINATED · PHASE3
• VictORION-INCLUSION: Evaluating Inclisiran for Cholesterol Managment in Heart Disease — ACTIVE_NOT_RECRUITING · PHASE4
• A randomized, double-blind, placebo -controlled, multicenter trial, assessing the impact of inclisiran on major adverse cardiovascular events in participants with established cardiovascular disease (VICTORION-2 PREVENT) — TERMINATED · PHASE3
• Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease — ACTIVE_NOT_RECRUITING · PHASE3
• A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a) — ACTIVE_NOT_RECRUITING · PHASE3
• The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes) — ACTIVE_NOT_RECRUITING · PHASE3
• Clinical Assessment and Targeted Imaging to Characterize High-Risk Atherosclerotic Cardiovascular Disease of Survivors in SJLIFE — NOT_YET_RECRUITING
• Effect of Secukinumab on Cardiorenal Outcomes in Patients With Cardiorenal Metabolic Syndrome and Atherosclerotic Cardiovascular Disease — NOT_YET_RECRUITING · PHASE4
• Low-Density Lipoprotein Cholesterol Reduction With Alirocumab 150 mg Versus Inclisiran in Individuals Initiating Therapy in Routine Clinical Practice — COMPLETED
• Reducing Inflammation to Improve Vascular and Bone Outcomes With Low-dose Colchicine in CKD — NOT_YET_RECRUITING · PHASE2
• The Belgian REAL (BE.REAL) Registry — ACTIVE_NOT_RECRUITING
• A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel-group Study to Assess the Effect of AZD0780 on Major Adverse Cardiovascular Events in Patients with Established Atherosclerotic Cardiovascular Disease (ASCVD) or at High Risk for a First ASCVD Event — TERMINATED · PHASE3
• Target-Oriented Strategy of Ultra-Low LDL-C (<1.0 vs. 1.0-1.39 mmol/L) in Extreme-High-Risk ASCVD Patients: Clinical Benefit, Safety and Cost-Effectiveness Assessment — NOT_YET_RECRUITING · NA
• A Randomized Trial Assessing the Effects of Inclisiran on Clinical Outcomes Among People With Cardiovascular Disease — ACTIVE_NOT_RECRUITING · PHASE3
• Comparative Effectiveness of Tirzepatide Versus Sitagliptin in Individuals at Cardiovascular Risk (TIRZSITA-CVOT) — COMPLETED
• A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRx) in Adults With Hypertriglyceridemia and Atherosclerotic Cardiovascular Disease (Established or at Increased Risk for), and/or With Severe Hypertriglyceridemia — COMPLETED · PHASE2
• Health Enhanced Artery Risk Tracking With Widespread Implementation and Screening Effort in ASCVD (HEARTWISE-ASCVD) — NOT_YET_RECRUITING · NA
• Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction (OCEAN(a)) - Outcomes Trial — ACTIVE_NOT_RECRUITING · PHASE3
• A Study to Assess the Effect of AZD0780 on Ambulatory Blood Pressure — COMPLETED · PHASE2
• Focus on Levels of Awareness and Perceptions Regarding hsCRP in Identifying Systemic Inflammation in ASCVD, CKD and Heart Failure Management — COMPLETED
• NOTIFY (New Observations Taking Information From Yesterday) — WITHDRAWN · NA
• A Master Protocol for Semaglutide Effects on Cardiovascular and Obesity-related Outcomes in People With Overweight or Obesity in the Real World — COMPLETED
• Effects of Berberine on Preventing Cardiovascular Disease and Diabetes Mellitus — ACTIVE_NOT_RECRUITING · PHASE4
• Phase IIa Clinical Trial of YN001 in Patients With Atherosclerotic Cardiovascular and Cerebrovascular Diseases and Erectile Dysfunction — NOT_YET_RECRUITING · PHASE2
• A Disease Area Study on the Awareness and Perceptions of Systemic Inflammation and hsCRP as a biomARKer in Patients With ASCVD and CKD in China Among Cardiologists and Nephrologists — COMPLETED

Refine this search